Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testosterone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.83 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.66 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.66 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.66 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.66 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.66 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Testosterone Propionate SCHEMBL30829229 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL4044 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL5460173 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL8724796 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL14360596 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL25083388 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL18438872 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL21256102 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL22417524 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRMAPTNR3C1 | |
| Testosterone Propionate SCHEMBL28227392 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNATSHRMAPTNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2023086471-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230143609-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220387447-A1 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | UNIV TEXAS (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3529251-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-20220152033-A1 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2019178536-A1 | MTOR INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190091239-A1 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | MEDCARA PHARMACEUTICALS, LLC | 2019-03-28 | — | — | US | disclosed |
| WO-2018073788-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | WO | disclosed |
| EP-3124616-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF TESTOSTERONE AND ESTERS THEREOF | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143609-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY | NDUFB6, HSD17B7, NDUFB7 | AR 182/4885CYP3A4 557/4885LMNA 807/4885 |
| US-20220152033-A1 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | FDFT1, SQLE, DSC1 | AR 223/4885CYP3A4 1074/4885LMNA 1384/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | AR 2737/4885CYP3A4 928/4885LMNA 1180/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | AR 3445/4885CYP3A4 1589/4885LMNA 1817/4885 |
| US-20190091239-A1 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | SHBG, NR5A1, CYP17A1 | AR 8/4885CYP3A4 1092/4885LMNA 1671/4885 |
| US-20220387447-A1 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | SHBG, NR5A1, CYP17A1 | AR 8/4885CYP3A4 1092/4885LMNA 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.